id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
24163322_4 | Warfarin was initiated for deep vein thrombosis prophylaxis due to the patient's inability to ambulate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prophylaxis\"]], \"start\": [[48]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"patient's inability to ambulate\"]], \"start\": [[71]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"inability to ambulate\"]], \"start\": [[81]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"Warfarin was initiated for deep vein thrombosis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"deep vein thrombosis\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"a\"]], \"start\": [[4]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
16432996_4 | We report a case with chronic hepatitis C (CHC) who developed sarcoidosis after the treatment by interferon alpha and ribavirin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[52]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"sarcoidosis\"]], \"start\": [[62]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"treatment by interferon alpha and ribavirin\"]], \"start\": [[84]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"chronic hepatitis C (CHC)\"]], \"start\": [[22]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"interferon alpha\"], [\"ribavirin\"]], \"start\": [[97], [118]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[114]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"interferon alpha\"], [\"ribavirin\"]], \"start\": [[97], [118]], \"entity_id\": [\"T13\", \"T14\"]}}]}}"
}
]
}
] |
15785053_2 | The relation between tacrolimus treatment and staining was suggested by the appearance of pigmentation during topical tacrolimus treatment and its clinical disappearance when treatment was stopped. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[103]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"topical tacrolimus\"]], \"start\": [[110]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"tacrolimus\"]], \"start\": [[118]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"topical\"]], \"start\": [[110]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"appearance of pigmentation\"]], \"start\": [[76]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8239963_3 | Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of clonidine-induced bradycardia is less well recognized and is rare. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[123]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"clonidine\"]], \"start\": [[113]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"clonidine\"]], \"start\": [[113]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"bradycardia\"]], \"start\": [[131]], \"entity_id\": [\"T11\"]}, \"Speculated\": {\"text\": [[\"possibility\"]], \"start\": [[98]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
16540070_3 | Several hypersensitivity reactions to cloxacillin have been reported, although IgE-mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reactions to\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"hypersensitivity\"]], \"start\": [[8]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"cloxacillin\"]], \"start\": [[38]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"cloxacillin\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
17547624_1 | Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Brugada type electrocardiographic changes\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"concomitant use of lithium and propafenone\"]], \"start\": [[53]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"Wolff-Parkinson-White syndrome\"]], \"start\": [[112]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"lithium\"], [\"propafenone\"]], \"start\": [[72], [84]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concomitant\"]], \"start\": [[53]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"lithium\"], [\"propafenone\"]], \"start\": [[72], [84]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Subject\": {\"text\": [[\"patient with Wolff-Parkinson-White syndrome\"]], \"start\": [[99]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17404582_2 | Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Meibomian duct inflammation and blockage leading to chalazion formation\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Docetaxel\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Docetaxel\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15628319_1 | Allergic side effects of AZA are rare, and reported allergic skin eruptions from AZA are very limited in Japan. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[76]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"allergic skin eruptions\"]], \"start\": [[52]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"AZA\"]], \"start\": [[81]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"AZA\"]], \"start\": [[81]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11212595_1 | Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[101]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"obsessive-compulsive symptoms (OCS)\"], [\"OCS\"]], \"start\": [[15], [109]], \"entity_id\": [\"T7\", \"T6\"]}, \"Treatment\": {\"text\": [[\"antipsychotic\"]], \"start\": [[87]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"antipsychotic\"]], \"start\": [[87]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
17852449_1 | Outcome of pregnancy in women treated with all-trans retinoic acid; a case report and review of literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[30]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"all-trans retinoic acid\"]], \"start\": [[43]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"all-trans retinoic acid\"]], \"start\": [[43]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"pregnancy\"]], \"start\": [[11]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"pregnancy in women\"]], \"start\": [[11]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"women\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
19687711_6 | The potential development of SJS/TEN, a severe life-threatening illness, emphasizes the need for judicious use of TMP-Sx and close monitoring and follow-up for patients who were given TMP-Sx for SSTIs. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"SJS/TEN, a severe life-threatening illness\"]], \"start\": [[29]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[160]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"TMP-Sx\"]], \"start\": [[184]], \"entity_id\": [\"T15\"], \"Disorder\": {\"text\": [[\"SSTIs\"]], \"start\": [[195]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"TMP\"], [\"Sx\"]], \"start\": [[184], [188]], \"entity_id\": [\"T21\", \"T22\"]}, \"Combination\": [{\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"-\"]], \"start\": [[187]], \"entity_id\": [\"T20\"]}, \"Drug\": {\"text\": [[\"TMP\"], [\"Sx\"]], \"start\": [[184], [188]], \"entity_id\": [\"T21\", \"T22\"]}}]}}"
}
]
}
] |
665845_1 | A case history of a 15-year-old boy who developed incapacitating tardive dyskinesia that resolved during treatment with deanol is presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[89]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a 15-year-old boy\"]], \"start\": [[18]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"15-year-old\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"incapacitating tardive dyskinesia\"]], \"start\": [[50]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"deanol\"]], \"start\": [[120]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"deanol\"]], \"start\": [[120]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
12187348_2 | Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[5]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"mammary hyperplasias\"]], \"start\": [[13]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Drug\", \"D-penicillamine and Neothetazone\"]], \"start\": [[0, 78]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Drug\"], [\"Neothetazone\"], [\"D-penicillamine\"]], \"start\": [[0], [98], [78]], \"entity_id\": [\"T9\", \"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[94]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"D-penicillamine\"], [\"Neothetazone\"]], \"start\": [[78], [98]], \"entity_id\": [\"T11\", \"T10\"]}}]}}"
}
]
}
] |
10482872_2 | The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exposure\"]], \"start\": [[68]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"CP\"]], \"start\": [[65]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"CP\"]], \"start\": [[65]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"multiple congenital anomalies\", \"CP embryopathy\"]], \"start\": [[82, 141]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
18176653_2 | AIM: The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of the antiretroviral medication Nevirapine (NVP). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[122]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"adverse effect\"]], \"start\": [[98]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"antiretroviral medication Nevirapine (NVP)\"]], \"start\": [[142]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Nevirapine\"]], \"start\": [[168]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16484748_1 | A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[249]], \"entity_id\": [\"T31\"]}, \"Treatment\": {\"text\": [[\"trimethoprim (TMP)-sulfamethoxazole (SMX)\"]], \"start\": [[259]], \"entity_id\": [\"T32\"], \"Drug\": {\"text\": [[\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[259], [278]], \"entity_id\": [\"T38\", \"T39\"]}, \"Time_elapsed\": {\"text\": [[\"two weeks after\"]], \"start\": [[233]], \"entity_id\": [\"T41\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"-\"]], \"start\": [[277]], \"entity_id\": [\"T40\"]}, \"Drug\": {\"text\": [[\"sulfamethoxazole\"], [\"trimethoprim\"]], \"start\": [[278], [259]], \"entity_id\": [\"T39\", \"T38\"]}}]}, \"Effect\": {\"text\": [[\"fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia\"]], \"start\": [[123]], \"entity_id\": [\"T33\"]}, \"Subject\": {\"text\": [[\"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia\"]], \"start\": [[0]], \"entity_id\": [\"T34\"], \"Age\": {\"text\": [[\"27-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T35\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T36\"]}, \"Disorder\": {\"text\": [[\"bronchial asthma\"], [\"eosinophilic enteritis\"], [\"eosinophilic pneumonia\"]], \"start\": [[39], [57], [85]], \"entity_id\": [\"T37\", \"T44\", \"T45\"]}}}"
}
]
}
] |
14674674_4 | Treatment with infliximab is known to produce an increase of autoantibodies (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"produce\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Treatment with infliximab\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"infliximab\"]], \"start\": [[15]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"increase of autoantibodies (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease\"]], \"start\": [[49]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
16882112_2 | Serotonin syndrome, which occurs as a result of enhanced serotonin concentration in the central nervous system, is a well-known adverse effect of serotonin-active medications. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurs\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Serotonin syndrome,\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"serotonin-active medications\"]], \"start\": [[146]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11424102_5 | Despite the risk of needle-track seeding, PEI remains useful in the treatment of HCC. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"remains\"]], \"start\": [[46]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"PEI\"]], \"start\": [[42]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"PEI\"]], \"start\": [[42]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"HCC\"]], \"start\": [[81]], \"entity_id\": [\"T12\"]}}, \"Speculated\": {\"text\": [[\"risk\"]], \"start\": [[12]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
20412003_4 | Trimethoprim-sulfamethoxazole-induced hepatotoxicity in a pediatric patient. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a pediatric patient\"]], \"start\": [[56]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"pediatric\"]], \"start\": [[58]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"Trimethoprim-sulfamethoxazole\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[0], [13]], \"entity_id\": [\"T2\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"-\"]], \"start\": [[12]], \"entity_id\": [\"T1\"]}, \"Drug\": {\"text\": [[\"Trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[0], [13]], \"entity_id\": [\"T2\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10589077_3 | Prolonged responses were achieved with low doses of HU (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or hepatic toxicity and no further increases in Hb. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[94]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"HU (3-10 mg/kg/day) and higher doses\"]], \"start\": [[52]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"HU\"]], \"start\": [[52]], \"entity_id\": [\"T15\"]}, \"Dosage\": {\"text\": [[\"higher doses\"]], \"start\": [[76]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"mild reversible hematologic or hepatic toxicity and no further increases in Hb\"]], \"start\": [[110]], \"entity_id\": [\"T6\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"achieved\"]], \"start\": [[25]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"low doses of HU\"]], \"start\": [[39]], \"entity_id\": [\"T10\"], \"Dosage\": {\"text\": [[\"low doses\"]], \"start\": [[39]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"HU\"]], \"start\": [[52]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"Prolonged responses\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
8276031_1 | Imidazoline intoxication in children. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"intoxication\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"children\"]], \"start\": [[28]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"children\"]], \"start\": [[28]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"Imidazoline\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Imidazoline\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"Imidazoline intoxication\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
19782276_10 | Concomitant administration of cytarabine might have affected his liver function and there might have been interaction between the drugs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"affected\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"cytarabine\"]], \"start\": [[30]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"cytarabine\"]], \"start\": [[30]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"liver function\"]], \"start\": [[65]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"might\"]], \"start\": [[41]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
7351000_4 | The probability of developing acute leukemia in this study was not significantly correlated to the total cumulative dosage of Treosulfan. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developing\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"the total cumulative dosage of Treosulfan\"]], \"start\": [[95]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Treosulfan\"]], \"start\": [[126]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"acute leukemia\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[63]], \"entity_id\": [\"T4\"], \"value\": true}}"
}
]
}
] |
1584367_1 | Intraventricular vancomycin-induced cerebrospinal fluid eosinophilia: report of two patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[28]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Intraventricular vancomycin\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Route\": {\"text\": [[\"Intraventricular\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"vancomycin\"]], \"start\": [[17]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"cerebrospinal fluid eosinophilia\"]], \"start\": [[36]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"two patients.\"]], \"start\": [[80]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[80]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
3438585_6 | This case supports the view that in gold-induced pneumonitis a prolonged treatment with corticosteroids may be necessary, as lung function continued to improve. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"as\"]], \"start\": [[122]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"a prolonged treatment with corticosteroids\"]], \"start\": [[61]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"in gold-induced pneumonitis\"]], \"start\": [[33]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"gold\"], [\"corticosteroids\"]], \"start\": [[36], [88]], \"entity_id\": [\"T10\", \"T11\"]}}}"
}
]
}
] |
11443640_1 | Massive plasmocytosis due to methimazole-induced bone marrow toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"bone marrow toxicity\", \"Massive plasmocytosis\"]], \"start\": [[49, 0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"methimazole\"]], \"start\": [[29]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"methimazole\"]], \"start\": [[29]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15331204_4 | RESULTS: After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of diabetes diagnoses. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"achieve\"]], \"start\": [[265]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"6-month period of monotherapy with indapamide (2.5 mg/day)\"]], \"start\": [[145]], \"entity_id\": [\"T27\"], \"Duration\": {\"text\": [[\"6-month\"]], \"start\": [[145]], \"entity_id\": [\"T28\"]}, \"Drug\": {\"text\": [[\"indapamide\"]], \"start\": [[180]], \"entity_id\": [\"T29\"]}, \"Dosage\": {\"text\": [[\"2.5 mg/day\"]], \"start\": [[192]], \"entity_id\": [\"T30\"]}}, \"Subject\": {\"text\": [[\"one patient\"]], \"start\": [[207]], \"entity_id\": [\"T25\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[207]], \"entity_id\": [\"T26\"]}}, \"Effect\": {\"text\": [[\"glucose levels of all patients increased and achieve criteria of diabetes diagnoses\"]], \"start\": [[220]], \"entity_id\": [\"T13\"]}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"achieve\"]], \"start\": [[265]], \"entity_id\": [\"T14\"]}, \"Effect\": {\"text\": [[\"glucose levels of all patients increased and achieve criteria of diabetes diagnoses\"]], \"start\": [[220]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and fosinopril (10 mg/day)\"]], \"start\": [[9]], \"entity_id\": [\"T12\"], \"Time_elapsed\": {\"text\": [[\"4- to 14-month\"]], \"start\": [[15]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"indapamide\"], [\"fosinopril\"]], \"start\": [[72], [100]], \"entity_id\": [\"T19\", \"T20\"]}, \"Dosage\": {\"text\": [[\"2.5 mg/day\"], [\"10 mg/day\"]], \"start\": [[84], [112]], \"entity_id\": [\"T21\", \"T22\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[57]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"indapamide\"], [\"fosinopril\"]], \"start\": [[72], [100]], \"entity_id\": [\"T19\", \"T20\"]}}]}, \"Subject\": {\"text\": [[\"three patients\"]], \"start\": [[126]], \"entity_id\": [\"T23\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[126]], \"entity_id\": [\"T24\"]}}}"
}
]
}
] |
6453500_1 | A reversible toxic liver damage was observed in a non-alcoholic woman treated with disulfiram. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"damage\"]], \"start\": [[25]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"a non-alcoholic woman\"]], \"start\": [[48]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"non-alcoholic\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[64]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"disulfiram\"]], \"start\": [[83]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"disulfiram\"]], \"start\": [[83]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"reversible toxic liver damage\"]], \"start\": [[2]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10904571_1 | A 60 year-old woman with chronic renal failure developed acute proximal muscle weakness after receiving a regular dosage of colchicine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[47]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 60 year-old woman with chronic renal failure\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"60 year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"acute proximal muscle weakness\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"regular dosage of colchicine\"]], \"start\": [[106]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"chronic renal failure\"]], \"start\": [[25]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"colchicine\"]], \"start\": [[124]], \"entity_id\": [\"T11\"]}, \"Dosage\": {\"text\": [[\"regular dosage\"]], \"start\": [[106]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
9824032_2 | The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[96]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"niacin\"]], \"start\": [[57]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"niacin\"]], \"start\": [[57]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth\"]], \"start\": [[107]], \"entity_id\": [\"T10\"]}, \"Speculated\": {\"text\": [[\"uncertain\"]], \"start\": [[75]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
16404563_4 | Nocardia is an important opportunistic infectious agent in immunocompromised hosts, i.e. in patients taking corticosteroids. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"infectious agent\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"corticosteroids\"]], \"start\": [[108]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"corticosteroids\"]], \"start\": [[108]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"immunocompromised hosts\"]], \"start\": [[59]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"immunocompromised\"]], \"start\": [[59]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Nocardia\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
8835752_1 | Hepatobiliary disorders associated with orally administered terbinafine have rarely been reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Hepatobiliary disorders\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"orally administered terbinafine\"]], \"start\": [[40]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"terbinafine\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"orally\"]], \"start\": [[40]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
3790438_2 | We report a patient in whom the anti-depressant trazodone hydrochloride (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (GPP). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"provoked\"]], \"start\": [[118]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"trazodone hydrochloride (Molipaxin, Roussel)\"]], \"start\": [[48]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"trazodone hydrochloride\"]], \"start\": [[48]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"generalized pustular psoriasis (GPP)\"]], \"start\": [[127]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[10]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
11703329_1 | Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"can\"]], \"start\": [[68]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Early recognition of hereditary motor and sensory neuropathy type 1\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Severity\": {\"text\": [[\"life-threatening\"]], \"start\": [[78]], \"entity_id\": [\"T6\"], \"value\": \"High\"}}"
}
]
}
] |
19299370_3 | Probable enoxaparin-induced hepatotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"enoxaparin\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"enoxaparin\"]], \"start\": [[9]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12581772_1 | Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[25]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Interstitial pneumonitis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"sirolimus\"]], \"start\": [[41]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sirolimus\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
19667003_15 | He had also developed elevated serum ammonia levels while on valproic acid. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"He\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"He\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"elevated serum ammonia levels\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"valproic acid\"]], \"start\": [[61]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"valproic acid\"]], \"start\": [[61]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16641839_4 | Cutaneous rashes and eruptions can be caused by many medications, including carbamazepine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Cutaneous rashes and eruptions\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"carbamazepine\"]], \"start\": [[76]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[76]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8140860_5 | In this case, the increase in the INR value with associated bruising after the addition of amoxycillin suggests a drug interaction between acenocoumarol and amoxycillin, other possible causes having been eliminated. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[69]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"the increase in the INR value with associated bruising\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"amoxycillin\"]], \"start\": [[91]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"amoxycillin\"], [\"acenocoumarol\"], [\"amoxycillin\"]], \"start\": [[91], [139], [157]], \"entity_id\": [\"T11\", \"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[119]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"acenocoumarol\"], [\"amoxycillin\"]], \"start\": [[139], [157]], \"entity_id\": [\"T13\", \"T14\"]}}]}, \"Speculated\": {\"text\": [[\"suggests\"]], \"start\": [[103]], \"entity_id\": [\"T15\"], \"value\": true}}"
}
]
}
] |
19897274_4 | Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[122]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sorafenib\"]], \"start\": [[96]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"sorafenib\"]], \"start\": [[96]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"lung cancer\"]], \"start\": [[51]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"serious interstitial lung disease\"]], \"start\": [[129]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"potentially\"]], \"start\": [[110]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
19667003_3 | SUMMARY: A 26-year-old man with bipolar disorder, seizures, and mild mental retardation secondary to a traumatic brain injury began treatment with carbamazepine for aggression and seizure control. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[132]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"carbamazepine\"]], \"start\": [[147]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[147]], \"entity_id\": [\"T16\"]}, \"Disorder\": {\"text\": [[\"aggression\"], [\"seizure\"]], \"start\": [[165], [180]], \"entity_id\": [\"T17\", \"T18\"]}}, \"Subject\": {\"text\": [[\"A 26-year-old man with bipolar disorder, seizures, and mild mental retardation secondary to a traumatic brain injury\"]], \"start\": [[9]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"bipolar disorder\", \"seizures\", \"mild mental retardation secondary to a traumatic brain injury\"]], \"start\": [[32, 50, 64]], \"entity_id\": [\"T11\"]}, \"Age\": {\"text\": [[\"26-year-old\"]], \"start\": [[11]], \"entity_id\": [\"T14\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[23]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
18676387_3 | Serotonin toxicity precipitated by fentanyl is unusual and has not previously been described in combination with SSRIs in the perioperative setting. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"precipitated\"]], \"start\": [[19]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"Serotonin toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"fentanyl\"]], \"start\": [[35]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"fentanyl\"], [\"SSRIs\"]], \"start\": [[35], [113]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[96]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"fentanyl\"], [\"SSRIs\"]], \"start\": [[35], [113]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Speculated\": {\"text\": [[\"unusual\"]], \"start\": [[47]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
16889287_1 | It may cause a severe adverse drug reaction with multiorgan involvement known as dapsone hypersensitivity syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[7]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"dapsone\"]], \"start\": [[81]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"dapsone\"]], \"start\": [[81]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity syndrome\"], [\"a severe adverse drug reaction\"]], \"start\": [[89], [13]], \"entity_id\": [\"T4\", \"T5\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[3]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
15806568_3 | Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Visual system side effects caused by parasympathetic dysfunction\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"botulinum toxin type B injections\"]], \"start\": [[71]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"botulinum toxin type B\"]], \"start\": [[71]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"injections\"]], \"start\": [[94]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
1124417_2 | Renal failure associated with acetazolamide therapy for glaucoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Renal failure\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"acetazolamide therapy\"]], \"start\": [[30]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"acetazolamide\"]], \"start\": [[30]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"glaucoma\"]], \"start\": [[56]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
12424571_1 | Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Acute onset of nephrotic syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"interferon-alpha retreatment\"]], \"start\": [[41]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"chronic active hepatitis C\"]], \"start\": [[74]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
12587815_1 | A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"while\"]], \"start\": [[131]], \"entity_id\": [\"T16\"]}, \"Subject\": {\"text\": [[\"A 16-year-old boy\"]], \"start\": [[0]], \"entity_id\": [\"T13\"], \"Age\": {\"text\": [[\"16-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T17\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[14]], \"entity_id\": [\"T18\"]}}, \"Treatment\": {\"text\": [[\"olanzapine and lithium\"]], \"start\": [[162]], \"entity_id\": [\"T14\"], \"Drug\": {\"text\": [[\"olanzapine\"], [\"lithium\"]], \"start\": [[162], [177]], \"entity_id\": [\"T19\", \"T21\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[173]], \"entity_id\": [\"T20\"]}, \"Drug\": {\"text\": [[\"olanzapine\"], [\"lithium\"]], \"start\": [[162], [177]], \"entity_id\": [\"T19\", \"T21\"]}}]}, \"Effect\": {\"text\": [[\"fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels\"]], \"start\": [[28]], \"entity_id\": [\"T15\"]}}"
}
]
}
] |
17526968_4 | The hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the skin toxicity of bleomycin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[133]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"bleomycin\"]], \"start\": [[145]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"bleomycin\"]], \"start\": [[145]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hyperpigmentation was diffuse scattered, flagellate like and linear streaking\"]], \"start\": [[4]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"mainly\"]], \"start\": [[106]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
11243427_5 | Exacerbation of 5-FU dermatologic toxicities in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre-existing dermatologic conditions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicities\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"dermatologic toxicities\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"5-FU\"]], \"start\": [[16]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[16]], \"entity_id\": [\"T4\"]}}}"
}
]
}
] |
2295443_1 | Bowel perforation associated with intraperitoneal chromic phosphate instillation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[18]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intraperitoneal chromic phosphate instillation\"]], \"start\": [[34]], \"entity_id\": [\"T4\"], \"Route\": {\"text\": [[\"intraperitoneal\", \"instillation\"]], \"start\": [[34, 68]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"chromic phosphate\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Bowel perforation\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
2224786_1 | A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related hemolytic-uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate\"]], \"start\": [[157]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"squamous cell carcinoma of the head and neck\"]], \"start\": [[46]], \"entity_id\": [\"T12\"]}, \"Dosage\": {\"text\": [[\"second cycle\"]], \"start\": [[161]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"cisplatin\"], [\"bleomycin\"], [\"methotrexate\"]], \"start\": [[216], [227], [242]], \"entity_id\": [\"T14\", \"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"consisting of\"]], \"start\": [[202]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"cisplatin\"], [\"bleomycin\"], [\"methotrexate\"]], \"start\": [[216], [227], [242]], \"entity_id\": [\"T14\", \"T15\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"a chemotherapy-related hemolytic-uremic syndrome\"]], \"start\": [[101]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"62-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
10466445_7 | These data confirm the therapeutic value of arsenic trioxide in relapsed/resistant APL. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"therapeutic value\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"arsenic trioxide\"]], \"start\": [[44]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"relapsed/resistant APL\"]], \"start\": [[64]], \"entity_id\": [\"T5\"]}}}"
}
]
}
] |
11373877_1 | Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Avascular necrosis of the femoral head\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"patients with prostate cancer\"]], \"start\": [[42]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cyproterone acetate and radiotherapy\"]], \"start\": [[85]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"prostate cancer\"]], \"start\": [[56]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"cyproterone acetate\"]], \"start\": [[85]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
11243427_4 | Ectropion secondary to bolus injection of 5-fluorouracil. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Ectropion\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"bolus injection of 5-fluorouracil\"]], \"start\": [[23]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"bolus injection\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"5-fluorouracil\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
2595431_1 | Metoclopramide-induced parkinsonism is not rare, and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Metoclopramide\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Metoclopramide\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"parkinsonism\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients with renal failure\"]], \"start\": [[83]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"renal failure\"]], \"start\": [[97]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
19307676_1 | Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[45]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Posterior reversible encephalopathy syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methotrexate neurotoxicity\"]], \"start\": [[61]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[61]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
25407257_4 | A 6-year-old boy (weight: 16 kg, at the start of treatment) began sodium valproate (valproate syrup 5%) treatment for epilepsy in February 2012. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[104]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 6-year-old boy (weight: 16 kg, at the start of treatment)\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"6-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[13]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"sodium valproate (valproate syrup 5%)\"]], \"start\": [[66]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"epilepsy\"]], \"start\": [[118]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"sodium valproate\"]], \"start\": [[66]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
3465489_1 | Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[87]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"6-mercaptopurine\"]], \"start\": [[32]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"6-mercaptopurine\"]], \"start\": [[32]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"acute lymphoblastic leukemia\"]], \"start\": [[104]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"myelotoxicity and therapeutic failure\"]], \"start\": [[49]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"children with acute lymphoblastic leukemia\"]], \"start\": [[90]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"children\"]], \"start\": [[90]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
8816294_2 | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[146]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"identical twin brothers\"]], \"start\": [[32]], \"entity_id\": [\"T7\"], \"Gender\": {\"text\": [[\"brothers\"]], \"start\": [[47]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"leukoencephalopathy and hydrocephalus\"]], \"start\": [[156]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"intrathecally administered methotrexate\", \"intrathecally administered methotrexate and cranial irradiation\"]], \"start\": [[262, 324]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"methotrexate\"], [\"methotrexate\"]], \"start\": [[289], [351]], \"entity_id\": [\"T12\", \"T15\"]}, \"Route\": {\"text\": [[\"intrathecally\"], [\"intrathecally\"]], \"start\": [[262], [324]], \"entity_id\": [\"T13\", \"T14\"]}}}"
}
]
}
] |
15735923_8 | Considering the increasing use of TMZ, which is regarded as a drug with moderate toxicity, careful follow-up with routine blood testing is vital. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"moderate toxicity\"]], \"start\": [[72]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"TMZ\"]], \"start\": [[34]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"TMZ\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11093071_3 | While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent changes in serotonergic or noradrenergic neurotransmission caused by IFN-alpha. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prevent\"]], \"start\": [[94]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"antidepressants\"]], \"start\": [[74]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"changes in serotonergic or noradrenergic neurotransmission caused by IFN-alpha\"]], \"start\": [[102]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"antidepressants\"]], \"start\": [[74]], \"entity_id\": [\"T6\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[90]], \"entity_id\": [\"T7\"], \"value\": true}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[161]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"IFN-alpha\"]], \"start\": [[171]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"IFN-alpha\"]], \"start\": [[171]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"changes in serotonergic or noradrenergic neurotransmission\"]], \"start\": [[102]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
17381671_2 | To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[39]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"nteraction between fentanyl and citalopram\"]], \"start\": [[56]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"fentanyl\"], [\"citalopram\"]], \"start\": [[75], [88]], \"entity_id\": [\"T8\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E1\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[55]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"fentanyl\"], [\"citalopram\"]], \"start\": [[75], [88]], \"entity_id\": [\"T8\", \"T11\"]}}]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[10]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
2586773_2 | We report a case of ibuprofen-induced meningitis in an otherwise healthy individual. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ibuprofen\"]], \"start\": [[20]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ibuprofen\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"meningitis\"]], \"start\": [[38]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an otherwise healthy individual\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10482872_3 | The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"shared\"]], \"start\": [[60]], \"entity_id\": [\"T15\"]}, \"Effect\": {\"text\": [[\"growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly\"]], \"start\": [[114]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"in utero exposure to cyclosposphamide\"]], \"start\": [[22]], \"entity_id\": [\"T17\"], \"Drug\": {\"text\": [[\"cyclosposphamide\"]], \"start\": [[43]], \"entity_id\": [\"T19\"]}}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[105]], \"entity_id\": [\"T18\"]}}"
}
]
}
] |
2931445_1 | L-Thyroxine-induced leukopenia in a patient with Hashimoto's disease: involvement of suppressor-cytotoxic T cells. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"L-Thyroxine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"L-Thyroxine\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"Hashimoto's disease\"]], \"start\": [[49]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"leukopenia\"]], \"start\": [[20]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient with Hashimoto's disease\"]], \"start\": [[34]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
1295628_1 | Carbamazepine-induced systemic lupus erythematosus-like disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Carbamazepine\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Carbamazepine\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"systemic lupus erythematosus-like disease\"]], \"start\": [[22]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8038468_1 | CONCLUSIONS: This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[76]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"increase of INR\"]], \"start\": [[60]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an elderly patient\"]], \"start\": [[79]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[82]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"levamisole and 5-FU\", \"warfarin\"]], \"start\": [[137, 182]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"levamisole\"], [\"5-FU\"], [\"warfarin\"]], \"start\": [[137], [152], [182]], \"entity_id\": [\"T12\", \"T14\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[148]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"levamisole\"], [\"5-FU\"], [\"warfarin\"]], \"start\": [[137], [152], [182]], \"entity_id\": [\"T12\", \"T14\", \"T15\"]}}]}, \"Severity\": {\"text\": [[\"significant\"]], \"start\": [[48]], \"entity_id\": [\"T11\"], \"value\": \"Medium\"}}"
}
]
}
] |
7653281_8 | These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; they also suggest that alcoholic beverages are not equivalent in their potential to cause liver damage. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"enhanced\"]], \"start\": [[81]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"hepatoxicity\"]], \"start\": [[31]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"alcoholic\"]], \"start\": [[58]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"alcoholic\"]], \"start\": [[58]], \"entity_id\": [\"T12\"]}}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[213]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
17671884_8 | The dermatology literature heretofore has not noted that anemia is a side effect of patients taking MMF to treat pemphigus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"is\"]], \"start\": [[64]], \"entity_id\": [\"T13\"]}, \"Effect\": {\"text\": [[\"anemia\"]], \"start\": [[57]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[84]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"MMF\"]], \"start\": [[100]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"pemphigus\"]], \"start\": [[113]], \"entity_id\": [\"T14\"]}}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[42]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
3430507_4 | The 9 other reported cases of D-penicillamine induced rapidly progressive glomerulonephritis have been reviewed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"D-penicillamine\"]], \"start\": [[30]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"D-penicillamine\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"rapidly progressive glomerulonephritis\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
15203443_2 | We describe a heroin abuser in whom clinical and laboratory manifestations of acute hepatitis B and C appeared a few days after the insertion of a subcutaneous naltrexone implant. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[122]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"subcutaneous naltrexone implant\"]], \"start\": [[147]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"heroin abuser\"]], \"start\": [[14]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"subcutaneous\"]], \"start\": [[147]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"naltrexone\"]], \"start\": [[160]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"acute hepatitis B and C\"]], \"start\": [[78]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a heroin abuser\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
1504404_2 | Ciprofloxacin-induced psychosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"psychosis\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15694139_2 | Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[53]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"teratogenic effects\"]], \"start\": [[82]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Thalidomide\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Thalidomide\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
24318743_1 | Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[24]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Weekly AUC2 carboplatin\", \"with or without oral phenoxodiol\"]], \"start\": [[0, 70]], \"entity_id\": [\"T8\"], \"Freq\": {\"text\": [[\"Weekly\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"AUC2 carboplatin\"], [\"phenoxodiol\"]], \"start\": [[7], [91]], \"entity_id\": [\"T11\", \"T13\"]}, \"Disorder\": {\"text\": [[\"platinum-resistant ovarian cancer\"]], \"start\": [[36]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[86]], \"entity_id\": [\"T7\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with or without\"]], \"start\": [[70]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"phenoxodiol\"], [\"AUC2 carboplatin\"]], \"start\": [[91], [7]], \"entity_id\": [\"T13\", \"T11\"]}}]}}"
}
]
}
] |
1688693_5 | We suggest the use of esmolol for treatment of dysrhythmias secondary to caffeine toxicity; to the best of our knowledge, the use of esmolol has not been reported for this purpose. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[34]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"esmolol\"]], \"start\": [[22]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"esmolol\"], [\"caffeine\"], [\"esmolol\"]], \"start\": [[22], [73], [133]], \"entity_id\": [\"T11\", \"T13\", \"T14\"]}, \"Disorder\": {\"text\": [[\"dysrhythmias\"]], \"start\": [[47]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
15806568_2 | To date, there have been few reports of visual disturbances associated with BTX-B use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"BTX-B\"]], \"start\": [[76]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"BTX-B\"]], \"start\": [[76]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"visual disturbances\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19116715_1 | Gemcitabine is a known risk factor for hemolytic uremic syndrome (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"risk\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hemolytic uremic syndrome\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[103]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"intervention\"]], \"start\": [[133]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"with steroids, plasmapheresis and hemodialysis\"]], \"start\": [[146]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"steroids\"], [\"plasmapheresis\"], [\"hemodialysis\"]], \"start\": [[151], [161], [180]], \"entity_id\": [\"T12\", \"T13\", \"T14\"]}, \"Disorder\": {\"text\": [[\"a rapidly fatal\"]], \"start\": [[93]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
16411025_4 | Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal MTX. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[126]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intrathecal MTX\"]], \"start\": [[132]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"intrathecal MTX\"]], \"start\": [[132]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"subacute neurotoxicity\"]], \"start\": [[103]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"four patients\"]], \"start\": [[76]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"four\"]], \"start\": [[76]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
17547624_2 | We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[99]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"administration of propafenone\", \"receiving lithium at concentrations within therapeutic levels\"]], \"start\": [[109, 196]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"propafenone\"], [\"lithium\"]], \"start\": [[127], [206]], \"entity_id\": [\"T10\", \"T3\"]}, \"Disorder\": {\"text\": [[\"Wolff-Parkinson-White syndrome\"]], \"start\": [[157]], \"entity_id\": [\"T1\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"administration\"]], \"start\": [[109]], \"entity_id\": [\"T2\"]}, \"Drug\": {\"text\": [[\"propafenone\"], [\"lithium\"]], \"start\": [[127], [206]], \"entity_id\": [\"T10\", \"T3\"]}}]}, \"Effect\": {\"text\": [[\"ST elevation in right precordial leads compatible with type 1 Brugada syndrome\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a patient with Wolff-Parkinson-White syndrome\"]], \"start\": [[142]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
25957434_2 | The spectrum of cutaneous eruptions associated with dihydropyridines is extensive, varying from exanthemas to severe adverse events. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"dihydropyridines\"]], \"start\": [[52]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"dihydropyridines\"]], \"start\": [[52]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"cutaneous eruptions\", \"exanthemas\"]], \"start\": [[16, 96]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
3365032_2 | Polymyositis after propylthiouracil treatment for hyperthyroidism. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Polymyositis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"propylthiouracil\"]], \"start\": [[19]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"propylthiouracil\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"hyperthyroidism\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8862924_2 | Methamphetamine's extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for injury to the cornea. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"offer\"]], \"start\": [[115]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Methamphetamine's\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"injury to the cornea\"]], \"start\": [[144]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"Methamphetamine's\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2956288_4 | Since ethambutol is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of ethambutol sufficient to produce optic neuropathy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"lead\"]], \"start\": [[127]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ethambutol\"]], \"start\": [[6]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[6]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"serum concentration elevations of ethambutol sufficient to produce optic neuropathy\"]], \"start\": [[135]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[123]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
788666_3 | Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml/min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq/liter, proteinuria, and cylindruria. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"beginning\"]], \"start\": [[42]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"gentamicin therapy\"]], \"start\": [[52]], \"entity_id\": [\"T3\"], \"Time_elapsed\": {\"text\": [[\"8 to 17 days\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"gentamicin\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Renal failure\", \"creatinine clearances 4 to 10 ml/min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq/liter, proteinuria, and cylindruria\"]], \"start\": [[0, 96]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8749646_2 | Seizures associated with ofloxacin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Seizures\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ofloxacin\"]], \"start\": [[25]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ofloxacin\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
11424102_1 | Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Cutaneous seeding\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"ultrasound-guided percutaneous ethanol injection\"]], \"start\": [[24]], \"entity_id\": [\"T8\"], \"Route\": {\"text\": [[\"injection\"]], \"start\": [[63]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"ethanol\"]], \"start\": [[55]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"hepatocellular carcinoma\"]], \"start\": [[90]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
19145124_3 | Two patients who developed decreased visual acuity after several months of ethambutol treatment for Mycobacterium avium-intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[51]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"Two patients\", \"Mycobacterium avium-intracellulare infection\"]], \"start\": [[0, 100]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"decreased visual acuity\", \"bitemporal visual field defects\", \"optic chiasm damage\"]], \"start\": [[27, 149, 196]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"ethambutol\"]], \"start\": [[75]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"Mycobacterium avium-intracellulare infection\"]], \"start\": [[100]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[75]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
9972383_1 | CONCLUSIONS: Metoclopramide may cause reversible nonthrombocytopenic vascular-type palpable purpura. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Metoclopramide\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Metoclopramide\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"reversible nonthrombocytopenic vascular-type palpable purpura\"]], \"start\": [[38]], \"entity_id\": [\"T4\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[28]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
18784429_2 | CONCLUSIONS: Life-threatening adrenal suppression, requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high-dose methylprednisolone in late pregnancy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"requiring\"]], \"start\": [[51]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"hydrocortisone supplementation and intensive therapy\"]], \"start\": [[61]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"hydrocortisone\"]], \"start\": [[61]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"successfully treated\"]], \"start\": [[132]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a newborn, whose mother had received high-dose methylprednisolone in late pregnancy\"]], \"start\": [[156]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"newborn\"]], \"start\": [[158]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
17420198_2 | A case of extrapyramidal symptoms (EPS) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[40]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"extrapyramidal symptoms (EPS)\"]], \"start\": [[10]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"aripiprazole\"]], \"start\": [[68]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"aripiprazole\"]], \"start\": [[68]], \"entity_id\": [\"T16\"]}}, \"Subject\": {\"text\": [[\"a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented\"]], \"start\": [[84]], \"entity_id\": [\"T13\"], \"Gender\": {\"text\": [[\"man\"]], \"start\": [[86]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"developmental disabilities\"]], \"start\": [[95]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
2378415_1 | Although high-dose methotrexate has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a fatal rise in intracranial pressure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[158]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"high-dose methotrexate\"]], \"start\": [[9]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"primary osteogenic sarcoma\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[9]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[19]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"a fatal rise in intracranial pressure\"]], \"start\": [[165]], \"entity_id\": [\"T7\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[167]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
}
]
}
] |
20298401_11 | This case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of ILD in patients taking erlotinib. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[99]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"taking erlotinib\"]], \"start\": [[136]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[143]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[127]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"occurrence of ILD\"]], \"start\": [[106]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
16156485_1 | Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a focal seizure) of severe lithium-induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[202]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"a prolonged seizure\"]], \"start\": [[121]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"lithium\"]], \"start\": [[194]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[194]], \"entity_id\": [\"T10\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[202]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"lithium\"]], \"start\": [[194]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[194]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"a serotonin syndrome\"]], \"start\": [[142]], \"entity_id\": [\"T13\"]}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[202]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"lithium\"]], \"start\": [[194]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[194]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"a focal seizure\"]], \"start\": [[167]], \"entity_id\": [\"T14\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[187]], \"entity_id\": [\"T15\"], \"value\": \"High\"}}"
},
{
"event_id": "E4",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E4\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"underwent\"]], \"start\": [[238]], \"entity_id\": [\"T17\"]}, \"Treatment\": {\"text\": [[\"ECT\"]], \"start\": [[248]], \"entity_id\": [\"T18\"], \"Disorder\": {\"text\": [[\"lithium-induced side effects\"]], \"start\": [[194]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"ECT\"]], \"start\": [[248]], \"entity_id\": [\"T19\"]}}, \"Effect\": {\"text\": [[\"without complications and lithium serum levels were still subtherapeutic\"]], \"start\": [[252]], \"entity_id\": [\"T20\"]}}"
}
]
}
] |
8363533_3 | Lithium-associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[8]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"4 Chinese women with autoimmune thyroiditis\"]], \"start\": [[47]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"4\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}, \"Race\": {\"text\": [[\"Chinese\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[57]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"autoimmune thyroiditis\"]], \"start\": [[68]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"Lithium\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Lithium\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"transient thyrotoxicosis\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
2006943_2 | A patient, while on intravenous ritodrine therapy for preterm labor, experienced an episode of acute chest pain. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"on\"]], \"start\": [[17]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"intravenous ritodrine therapy\"]], \"start\": [[20]], \"entity_id\": [\"T8\"], \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[20]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"ritodrine\"]], \"start\": [[32]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"an episode of acute chest pain\"]], \"start\": [[81]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"A patient\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
4095247_2 | Subsequent in vivo/vitro studies clearly demonstrated that the neurological effects were due to a synergistic action of desferrioxamine and prochlorperazine, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[89]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"desferrioxamine and prochlorperazine\"]], \"start\": [[120]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"desferrioxamine\"], [\"prochlorperazine\"]], \"start\": [[120], [140]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"synergistic\"]], \"start\": [[98]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"desferrioxamine\"], [\"prochlorperazine\"]], \"start\": [[120], [140]], \"entity_id\": [\"T7\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"neurological effects\"]], \"start\": [[63]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"probably\"]], \"start\": [[158]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
19725909_1 | Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"outcome\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"after liver transplantation with lamivudine and adefovir therapy\"]], \"start\": [[51]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"lamivudine\"], [\"adefovir\"]], \"start\": [[84], [99]], \"entity_id\": [\"T8\", \"T9\"]}, \"Disorder\": {\"text\": [[\"hepatitis B infection\"]], \"start\": [[29]], \"entity_id\": [\"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[95]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"lamivudine\"], [\"adefovir\"]], \"start\": [[84], [99]], \"entity_id\": [\"T8\", \"T9\"]}}]}}"
}
]
}
] |
6498095_3 | Pemphigus foliaceus was seen in a patient with pulmonary tuberculosis during rifampicin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"seen\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Pemphigus foliaceus\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient with pulmonary tuberculosis\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"rifampicin\"]], \"start\": [[77]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"pulmonary tuberculosis\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"rifampicin\"]], \"start\": [[77]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11816261_2 | CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[122]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[113]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose\"]], \"start\": [[132]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"sertraline\"], [\"venlafaxine\"], [\"metoclopramide\"]], \"start\": [[132], [146], [163]], \"entity_id\": [\"T14\", \"T15\", \"T16\"]}, \"Dosage\": {\"text\": [[\"single, conventional dose\"]], \"start\": [[206]], \"entity_id\": [\"T19\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"coadministered\"]], \"start\": [[181]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"metoclopramide\"], [\"venlafaxine\"], [\"sertraline\"]], \"start\": [[163], [146], [132]], \"entity_id\": [\"T16\", \"T15\", \"T14\"]}}]}, \"Effect\": {\"text\": [[\"serotonin syndrome with serious extrapyramidal reactions\"]], \"start\": [[53]], \"entity_id\": [\"T12\"]}, \"Speculated\": {\"text\": [[\"risk\"]], \"start\": [[45]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.